Oncology Institute (NASDAQ:TOI) Director Mark Pacala Sells 50,000 Shares

The Oncology Institute, Inc. (NASDAQ:TOI) Director Mark Pacala sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $4.00, for a total value of $200,000.00. Following the completion of the sale, the director owned 174,971 shares of the company’s stock, valued at approximately $699,884. This trade represents a 22.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Oncology Institute Stock Performance

Shares of NASDAQ TOI traded down $0.15 during trading hours on Friday, hitting $3.10. 378,261 shares of the company’s stock were exchanged, compared to its average volume of 1,666,279. The company’s 50-day moving average price is $3.78 and its 200-day moving average price is $3.35. The stock has a market capitalization of $289.38 million, a price-to-earnings ratio of -4.84 and a beta of 0.07. The company has a debt-to-equity ratio of 14.58, a current ratio of 1.68 and a quick ratio of 1.39. The Oncology Institute, Inc. has a 1-year low of $0.14 and a 1-year high of $4.88.

Oncology Institute (NASDAQ:TOI) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). Oncology Institute had a negative net margin of 13.21% and a negative return on equity of 1,527.21%. The firm had revenue of $136.56 million during the quarter, compared to analyst estimates of $122.63 million. Oncology Institute has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On Oncology Institute

Several institutional investors have recently made changes to their positions in the stock. Prelude Capital Management LLC acquired a new position in Oncology Institute during the third quarter valued at approximately $41,000. ProShare Advisors LLC bought a new position in shares of Oncology Institute during the second quarter valued at $25,000. BNP Paribas Financial Markets lifted its holdings in Oncology Institute by 141.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,119 shares of the company’s stock worth $42,000 after buying an additional 7,091 shares during the period. Sherbrooke Park Advisers LLC bought a new stake in Oncology Institute in the third quarter valued at approximately $51,000. Finally, Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Oncology Institute during the second quarter worth $32,000. 36.86% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on TOI. BTIG Research reaffirmed a “buy” rating and set a $7.00 target price on shares of Oncology Institute in a report on Tuesday, October 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncology Institute in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.00.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.